Biological applications of protein transduction technology

Trends in Biotechnology

Volumn 21, Issue 11, 2003, Pages 498-503

  Kabouridis, Panagiotis S ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOTECHNOLOGY; CELL MEMBRANES; CYTOLOGY; TISSUE;

PROTEIN TRANSDUCTION DOMAINS (PTD);

PROTEINS;

ARGINYLARGINYLARGINYLARGINYLARGINYLARGINYLARGININE; ARGINYLARGINYLGLUTAMINYLARGINYLARGINYLTHREONYLSERYLLYSYLLEUCYLMETHIONYLL YSY LARGININE; ARGINYLGLUTAMINYLISOLEUCYLLYSYLISOLEUCYLTRYPTOPHYLPHENYLALANYLGLUTAMINYL ASP ARAGINYLARGINYLARGINYLMETHIONYLLYSYLTRYPTOPHYLLYSYLLYSINE; GLYCYLTRYPTOPHYLTHREONYLLEUCYLASPARAGINYLSERYLALANYLGLYCYLTYROSYLLEUCYLL EUC YLGLYCYLLYSYLISOLEUCYLASPARAGINYLLEUCYLLYSYLALANYLLEUCYLALANYLALANYLLEUCYLALANYL LYSYLLYSYLISOLEUCYLLEUCINE; PEPTIDE; PROTEIN TRANSDUCTION DOMAIN; TRYPTOPHYLGLUTAMYLALANYLLYSYLLEUCYLALANYLLYSYLALANYLLEUCYLALANYLLYSYLALA NYL LEUCYLALANYLLYSYLHISTIDYLLEUCYLALANYLLYSYLALANYLLEUCYLALANYLLYSYLALANYLLEUCYLLYS YLALANYLCYSTEINYLGLUTAMYLALANINE; TYROSYLGLYCYLARGINYLLYSYLLYSYLARGINYLARGINYLGLUTAMINYLARGINYLARGINYLARGI NIN E; UNCLASSIFIED DRUG;

BIOTECHNOLOGY; CELL MEMBRANE PERMEABILITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN STRUCTURE; PROTEIN TRANSPORT; REVIEW; STRUCTURE ACTIVITY RELATION;

EID: 0142155259     PISSN: 01677799     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tibtech.2003.09.008     Document Type: Review

References (78)

1. Gomperts B.D., Fernandez J.M. Techniques for membrane permeabilization. Trends Biochem. Sci. 10:1985;414-417.
2. Chang D.C., et al. Guide to Electroporation and Electrofusion. 1991;Academic Press.
3. Celis J.E., et al. Microinjection and Organelle Transplantation Techniques. 1986;Academic Press.
4. Green M., Loewenstein P.M. Autonomous functional domains of chemically synthesized human immunodeficiency virus tat trans-activator protein. Cell. 55:1988;1179-1188.
5. Frankel A.D., Pabo C.O. Cellular uptake of the tat protein from human immunodeficiency virus. Cell. 55:1988;1189-1193.
6. Mann D.A., Frankel A.D. Endocytosis and targeting of exogenous HIV-1 Tat protein. EMBO J. 10:1991;1733-1739.
7. Prochiantz A. Messenger proteins: homeoproteins, TAT and others. Curr. Opin. Cell Biol. 12:2000;400-406.
8. Derossi D., et al. The third helix of the Antennapedia homeodomain translocates through biological membranes. J. Biol. Chem. 269:1994;10444-10450.
9. Elliott G., O'Hare P. Intercellular trafficking and protein delivery by a herpesvirus structural protein. Cell. 88:1997;223-233.
10. Lundberg M., Johansson M. Is VP22 nuclear homing an artifact? Nat. Biotechnol. 19:2001;713-714.
11. Pooga M., et al. Cell penetration by transportan. FASEB J. 12:1998;67-77.
12. Pooga M., et al. Cellular translocation of proteins by transportan. FASEB J. 15:2001;1451-1453.
13. Oehlke J., et al. Cellular uptake of an alpha-helical amphipathic model peptide with the potential to deliver polar compounds into the cell interior non-endocytically. Biochim. Biophys. Acta. 1414:1998;127-139.
14. Wyman T.B., et al. Design, synthesis, and characterization of a cationic peptide that binds to nucleic acids and permeabilizes bilayers. Biochemistry. 36:1997;3008-3017.
15. Schwarze S.R., et al. Protein transduction: unrestricted delivery into all cells? Trends Cell Biol. 10:2000;290-295.
16. Wadia J.S., Dowdy S.F. Protein transduction technology. Curr. Opin. Biotechnol. 13:2002;52-56.
17. Lindgren M., et al. Cell-penetrating peptides. Trends Pharmacol. Sci. 21:2000;99-103.
18. Gariepy J., Kawamura K. Vectorial delivery of macromolecules into cells using peptide-based vehicles. Trends Biotechnol. 19:2001;21-28.
19. Langel U. Cell-Penetrating Peptides, Processes and Applications. 2002;CRC Press.
20. Hawiger J. Cellular import of functional peptides to block intracellular signaling. Curr. Opin. Immunol. 9:1997;189-194.
21. Hawiger J. Noninvasive intracellular delivery of functional peptides and proteins. Curr. Opin. Chem. Biol. 3:1999;89-94.
22. Vives E., et al. A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus. J. Biol. Chem. 272:1997;16010-16017.
23. Buschle M., et al. Transloading of tumor antigen-derived peptides into antigen-presenting cells. Proc. Natl. Acad. Sci. U. S. A. 94:1997;3256-3261.
24. Wender P.A., et al. The design, synthesis, and evaluation of molecules that enable or enhance cellular uptake: peptoid molecular transporters. Proc. Natl. Acad. Sci. U. S. A. 97:2000;13003-13008.
25. Rothbard J.B., et al. Arginine-rich molecular transporters for drug delivery: role of backbone spacing in cellular uptake. J. Med. Chem. 45:2002;3612-3618.
26. Mai J.C., et al. Efficiency of protein transduction is cell type-dependent and is enhanced by dextran sulfate. J. Biol. Chem. 277:2002;30208-30218.
27. Futaki S., et al. Arginine-rich peptides. An abundant source of membrane-permeable peptides having potential as carriers for intracellular protein delivery. J. Biol. Chem. 276:2001;5836-5840.
28. Suzuki T., et al. Possible existence of common internalization mechanisms among arginine-rich peptides. J. Biol. Chem. 277:2002;2437-2443.
29. Mi Z., et al. Characterization of a class of cationic peptides able to facilitate efficient protein transduction in vitro and in vivo. Mol. Ther. 2:2000;339-347.
30. Morris M.C., et al. A peptide carrier for the delivery of biologically active proteins into mammalian cells. Nat. Biotechnol. 19:2001;1173-1176.
31. Vives E., et al. TAT peptide internalization: seeking the mechanism of entry. Curr. Protein Pept. Sci. 4:2003;125-132.
32. Richard J.P., et al. Cell-penetrating peptides. A reevaluation of the mechanism of cellular uptake. J. Biol. Chem. 278:2003;585-590.
33. Drin, G. et al. Studies on the internalisation mechanism of cationic cell-penetrating peptides. J. Biol. Chem. (in press).
34. Fittipaldi, A. et al. Cell membrane lipid rafts mediate caveolar endocytosis of HIV-1 tat fusion proteins. J. Biol. Chem. (in press).
35. r cargo upon binding to cell surface glycosaminoglycans. J. Biol. Chem. (in press).
36. Lundberg M., Johansson M. Positively charged DNA-binding proteins cause apparent cell membrane translocation. Biochem. Biophys. Res. Commun. 291:2002;367-371.
37. Lundberg M., et al. Cell surface adherence and endocytosis of protein transduction domains. Mol. Ther. 8:2003;143-150.
38. Hallbrink M., et al. Cargo delivery kinetics of cell-penetrating peptides. Biochim. Biophys. Acta. 1515:2001;101-109.
39. Lindgren M., et al. Translocation properties of novel cell penetrating transportan and penetratin analogues. Bioconjug. Chem. 11:2000;619-626.
40. Tyagi M., et al. Internalization of HIV-1 tat requires cell surface heparan sulfate proteoglycans. J. Biol. Chem. 276:2001;3254-3261.
41. Ho A., et al. Synthetic protein transduction domains: enhanced transduction potential in vitro and in vivo. Cancer Res. 61:2001;474-477.
42. Nagahara H., et al. Transduction of full-length TAT fusion proteins into mammalian cells: TAT-p27Kip1 induces cell migration. Nat. Med. 4:1998;1449-1452.
43. Becker-Hapak M., et al. TAT-mediated protein transduction into mammalian cells. Methods. 24:2001;247-256.
44. Falnes P.O., et al. Ability of the Tat basic domain and VP22 to mediate cell binding, but not membrane translocation of the diphtheria toxin A-fragment. Biochemistry. 40:2001;4349-4358.
45. Fawell S., et al. Tat-mediated delivery of heterologous proteins into cells. Proc. Natl. Acad. Sci. U. S. A. 91:1994;664-668.
46. Abu-Am Y., et al. TAT fusion proteins containing tyrosine 42-deleted IκBα arrest osteoclastogenesis. J. Biol. Chem. 276:2001;30499-30503.
47. Kabouridis P.S., et al. Inhibition of NF-κB activity by a membrane-transducing mutant of IκBα J. Immunol. 169:2002;2587-2593.
48. May M.J., et al. Selective inhibition of NF-κB activation by a peptide that blocks the interaction of NEMO with the IκB kinase complex. Science. 289:2000;1550-1554.
49. Rehman K.K., et al. Protection of islets by in situ peptide-mediated transduction of the IκB kinase inhibitor NEMO-binding domain peptide. J. Biol. Chem. 278:2003;9862-9868.
50. Fujihara S.M., Nadler S.G. Intranuclear targeted delivery of functional NF-κB by 70 kDa heat shock protein. EMBO J. 18:1999;411-419.
51. Fujihara S.M., et al. A D-amino acid peptide inhibitor of NF-κB nuclear localization is efficacious in models of inflammatory disease. J. Immunol. 165:2000;1004-1012.
52. Yan Liu X., et al. Peptide-directed suppression of a pro-inflammatory cytokine response. J. Biol. Chem. 275:2000;16774-16778.
53. Myou S., et al. Blockade of focal clustering and active conformation in β2-integrin-mediated adhesion of eosinophils to intercellular adhesion molecule-1 caused by transduction of HIV TAT-dominant negative Ras. J. Immunol. 169:2002;2670-2676.
54. Vocero-Akbani A.M., et al. Killing HIV-infected cells by transduction with an HIV protease-activated caspase-3 protein. Nat. Med. 5:1999;29-33.
55. Ezhevsky S.A., et al. Hypo-phosphorylation of the retinoblastoma protein (pRb) by cyclin D:Cdk4/6 complexes results in active pRb. Proc. Natl. Acad. Sci. U. S. A. 94:1997;10699-10704.
56. Lissy N.A., et al. TCR antigen-induced cell death occurs from a late G1 phase cell cycle check point. Immunity. 8:1998;57-65.
57. Kato D., et al. Features of replicative senescence induced by direct addition of Antennapedia-p16INK4A fusion protein to human diploid fibroblasts. FEBS Lett. 427:1998;203-208.
58. Fahraeus R., et al. Characterization of the cyclin-dependent kinase inhibitory domain of the INK4 family as a model for a synthetic tumour suppressor molecule. Oncogene. 16:1998;587-596.
59. Mutoh M., et al. A p21(Waf1/Cip1)carboxyl-terminal peptide exhibited cyclin-dependent kinase-inhibitory activity and cytotoxicity when introduced into human cells. Cancer Res. 59:1999;3480-3488.
60. Lissy N.A., et al. A common E2F-1 and p73 pathway mediates cell death induced by TCR activation. Nature. 407:2000;642-645.
61. Cohen-Saidon, C. et al. A novel strategy using single chain antibody to show the importance of Bcl-2 in mast cell survival. Blood (in press).
62. Torchilin V.P., et al. TAT peptide on the surface of liposomes affords their efficient intracellular delivery even at low temperature and in the presence of metabolic inhibitors. Proc. Natl. Acad. Sci. U. S. A. 98:2001;8786-8791.
63. Rudolph C., et al. Oligomers of the arginine-rich motif of the HIV-1 TAT protein are capable of transferring plasmid DNA into cells. J. Biol. Chem. 278:2003;11411-11418.
64. Torchilin V.P., et al. Cell transfection in vitro and in vivo with nontoxic TAT peptide-liposome-DNA complexes. Proc. Natl. Acad. Sci. U. S. A. 100:2003;1972-1977.
65. Pooga M., et al. Cell penetrating PNA constructs regulate galanin receptor levels and modify pain transmission in vivo. Nat. Biotechnol. 16:1998;857-861.
66. Eguchi A., et al. Protein transduction domain of HIV-1 Tat protein promotes efficient delivery of DNA into mammalian cells. J. Biol. Chem. 276:2001;26204-26210.
67. Schwarze S.R., et al. In vivo protein transduction: delivery of a biologically active protein into the mouse. Science. 285:1999;1569-1572.
68. Bucci M., et al. In vivo delivery of the caveolin-1 scaffolding domain inhibits nitric oxide synthesis and reduces inflammation. Nat. Med. 6:2000;1362-1367.
69. Cao G., et al. In vivo delivery of a Bcl-xL fusion protein containing the TAT protein transduction domain protects against ischemic brain injury and neuronal apoptosis. J. Neurosci. 22:2002;5423-5431.
70. Jo D., et al. Epigenetic regulation of gene structure and function with a cell-permeable Cre recombinase. Nat. Biotechnol. 19:2001;929-933.
71. Peitz M., et al. Ability of the hydrophobic FGF and basic TAT peptides to promote cellular uptake of recombinant Cre recombinase: a tool for efficient genetic engineering of mammalian genomes. Proc. Natl. Acad. Sci. U. S. A. 99:2002;4489-4494.
72. Caron N.J., et al. Intracellular delivery of a Tat-eGFP fusion protein into muscle cells. Mol. Ther. 3:2001;310-318.
73. Xia H., et al. The HIV Tat protein transduction domain improves the biodistribution of β-glucuronidase expressed from recombinant viral vectors. Nat. Biotechnol. 19:2001;640-644.
74. Leifert J.A., et al. Full-length proteins attached to the HIV tat protein transduction domain are neither transduced between cells, nor exhibit enhanced immunogenicity. Gene Ther. 9:2002;1422-1428.
75. Cashman S.M., et al. Evidence of protein transduction but not intercellular transport by proteins fused to HIV tat in retinal cell culture and in vivo. Mol. Ther. 8:2003;130-142.
76. Gratton J.P., et al. Cell-permeable peptides improve cellular uptake and therapeutic gene delivery of replication-deficient viruses in cells and in vivo. Nat. Med. 9:2003;357-363.
77. Rothbard J.B., et al. Conjugation of arginine oligomers to cyclosporin A facilitates topical delivery and inhibition of inflammation. Nat. Med. 6:2000;1253-1257.
78. Lewin M., et al. Tat peptide-derivatized magnetic nanoparticles allow in vivo tracking and recovery of progenitor cells. Nat. Biotechnol. 18:2000;410-414.